⏳ Fetching live dividend data...
Home › Calculator › PHASQ Dividend Calculator 2026
PhaseBio Pharmaceuticals, Inc. · OTC
Price: $0.00 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in PHASQ → $1.02400512001152e+61M in 10 years · $853,337,173,341,013,400,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/month
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime.
Ready to invest? Open PHASQ position with:
Real after-tax yield depends on where you live and how you hold PHASQ.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 200000000.00% | 199999997.20% | $20,000,000,000 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 170000000.00% | 169999997.20% | $17,000,000,000 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 160000000.00% | 159999997.20% | $16,000,000,000 / yr |
| 🇬🇧 UK ISA | 0% | 200000000.00% | 199999997.20% | $20,000,000,000 / yr |
| 🇬🇧 UK Taxable | 8.75% | 182500000.00% | 182499997.20% | $18,250,000,000 / yr |
| 🇨🇦 TFSA | 0% | 200000000.00% | 199999997.20% | $20,000,000,000 / yr |
| 🇨🇦 CA Taxable | 25% | 150000000.00% | 149999997.20% | $15,000,000,000 / yr |
| 🇦🇺 Super (pension) | 15% | 170000000.00% | 169999997.20% | $17,000,000,000 / yr |
| 🇦🇺 AU Taxable | 30% | 140000000.00% | 139999997.20% | $14,000,000,000 / yr |
| 🇩🇪 DE Taxable | 26.375% | 147250000.00% | 147249997.20% | $14,725,000,000 / yr |
| 🇫🇷 FR Taxable | 30% | 140000000.00% | 139999997.20% | $14,000,000,000 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
PHASQ pays quarterly — 4 times per year. Next ex-div: TBD.
How PHASQ compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for PHASQ sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| M-Exempt | 2023-05-19 | 3,750 | — | — | ||
| A-Award | 2023-05-19 | 3,750 | — | — | ||
| M-Exempt | 2023-05-19 | 3,750 | — | — | ||
| M-Exempt | 2023-05-19 | 3,750 | — | — | ||
| M-Exempt | 2023-05-19 | 2,538 | — | — | ||
| M-Exempt | 2023-05-19 | 2,538 | — | — | ||
| M-Exempt | 2023-05-19 | 3,750 | — | — | ||
| M-Exempt | 2023-05-19 | 3,750 | — | — | ||
| M-Exempt | 2023-05-19 | 3,750 | — | — | ||
| M-Exempt | 2023-05-19 | 3,750 | — | — |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the PHASQ dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →